KANEKO YASUNORI 4

What Happened
Yasunori Kaneko, a director of Arcus Biosciences (RCUS), received two awards on June 11, 2026: a grant of 5,700 restricted stock units (RSUs) and an additional 16,900 derivative share awards. Both items were reported as acquisitions at $0 per share (typical for equity awards). These were grants/awards (not open‑market purchases or sales).

Key Details

• Transaction date: June 11, 2026; Form 4 filed June 12, 2026 (appears timely).
• Items reported:
  • 5,700 shares — Award/Grant (RSUs) at $0.00 (footnote F1).
  • 16,900 shares — Derivative award at $0.00 (footnotes F2/F3 reference prior vesting and option vesting terms).
• Footnotes:
  • F1: The 5,700 RSUs vest in full on the earlier of June 11, 2027 or the next annual meeting; vesting accelerates on a change in control.
  • F2: Notes that 13,300 RSUs (previously reported) vested on June 11, 2026 and were transferred to the reporting person's trust.
  • F3: Indicates an option-related award will vest in full on the earlier of June 11, 2027 or the next annual meeting and will accelerate on a change in control.
• Reported acquisition value: $0 (standard for equity grants).
• Shares owned after transaction: Not specified in the provided filing details.

Context

• These transactions are grants/awards (A) rather than purchases or sales; such awards are routine compensation/board grants and do not by themselves signal a buy or sell decision by the insider.
• Derivative items and option-related language in the footnotes indicate some awards are subject to future vesting and change‑in‑control acceleration — they are not immediately liquid shares unless vested.
• No indication in the provided data of a 10b5-1 plan, gift, or tax‑withholding sale associated with these entries.